Compare Stocks → Your $200 account credit is about to expire (From MarketBeat) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KODNASDAQ:MGTXNASDAQ:STRONASDAQ:TARS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$7.45+4.9%$5.29$1.37▼$9.80$372.55M2.17839,591 shs2.88 million shsMGTXMeiraGTx$6.21+0.8%$6.25$3.49▼$8.35$398.81M1.3153,611 shs140,061 shsSTROSutro Biopharma$4.93+17.9%$4.47$2.01▼$6.11$300.48M0.95906,647 shs1.83 million shsTARSTarsus Pharmaceuticals$34.57+2.2%$31.13$11.33▼$40.40$1.18B1.07779,182 shs410,039 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences+4.93%+28.89%+25.00%+129.94%+52.04%MGTXMeiraGTx+0.81%-4.31%+6.34%-12.78%+23.21%STROSutro Biopharma+17.94%+45.00%+2.60%+13.07%+7.17%TARSTarsus Pharmaceuticals+2.16%+2.52%+4.25%+66.76%+182.43%4x Better than Bitcoin (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKODKodiak Sciences3.441 of 5 stars0.93.00.04.63.13.31.3MGTXMeiraGTx4.6043 of 5 stars3.54.00.04.83.31.70.6STROSutro Biopharma4.6705 of 5 stars3.54.00.04.73.12.50.6TARSTarsus Pharmaceuticals3.4551 of 5 stars4.41.00.00.03.33.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKODKodiak Sciences1.83Reduce$6.75-9.40% DownsideMGTXMeiraGTx3.00Buy$25.67313.31% UpsideSTROSutro Biopharma3.00Buy$13.71178.18% UpsideTARSTarsus Pharmaceuticals2.88Moderate Buy$48.3839.93% UpsideCurrent Analyst RatingsLatest STRO, TARS, KOD, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024STROSutro BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.003/26/2024STROSutro BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $8.003/26/2024STROSutro BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$17.003/26/2024STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/6/2024TARSTarsus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $44.002/29/2024TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $30.002/28/2024TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $57.002/28/2024TARSTarsus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$40.00 ➝ $50.002/28/2024TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$55.00 ➝ $59.001/5/2024STROSutro BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKODKodiak SciencesN/AN/AN/AN/A$8.34 per shareN/AMGTXMeiraGTx$14.02M28.45N/AN/A$2.17 per share2.86STROSutro Biopharma$153.73M1.95N/AN/A$3.78 per share1.30TARSTarsus Pharmaceuticals$17.45M67.79N/AN/A$5.95 per share5.81Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKODKodiak Sciences-$333.82M-$5.18N/AN/AN/AN/A-73.87%-44.42%3/28/2024 (Confirmed)MGTXMeiraGTx-$84.03M-$1.47N/A6.90N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)STROSutro Biopharma-$119.20M-$1.78N/AN/AN/A-69.47%-71.28%-25.71%5/20/2024 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$4.64N/AN/AN/AN/A-74.28%-58.20%5/14/2024 (Estimated)Latest STRO, TARS, KOD, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AKODKodiak Sciences-$0.99-$0.77+$0.22N/AN/AN/A 2/27/202412/31/2023TARSTarsus Pharmaceuticals-$1.37-$1.31+$0.06-$1.31$4.63 million$13.08 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKODKodiak SciencesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKODKodiak SciencesN/A4.964.96MGTXMeiraGTx0.622.382.38STROSutro BiopharmaN/A5.185.18TARSTarsus Pharmaceuticals0.156.936.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKODKodiak Sciences89.06%MGTXMeiraGTx67.48%STROSutro Biopharma96.99%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipKODKodiak Sciences45.40%MGTXMeiraGTx9.70%STROSutro Biopharma6.90%TARSTarsus Pharmaceuticals11.54%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKODKodiak Sciences11652.47 million28.65 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableSTROSutro Biopharma29860.95 million56.75 millionOptionableTARSTarsus Pharmaceuticals24434.22 million30.27 millionOptionableSTRO, TARS, KOD, and MGTX HeadlinesSourceHeadlineTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by Analystsamericanbankingnews.com - March 24 at 1:14 AMTarsus Pharmaceuticals executive sells over $130k in company stockinvesting.com - March 21 at 8:19 PMTarsus Pharmaceuticals exec sells over $135k in stockinvesting.com - March 21 at 8:19 PMInsider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 10,415 Shares of Stockamericanbankingnews.com - March 20 at 7:14 AMBryan Wahl Sells 4,436 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stockinsidertrades.com - March 20 at 6:52 AMInsider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells 4,436 Shares of Stockmarketbeat.com - March 19 at 8:14 PMPill Targeting Tick-Induced Lyme Disease Shows Promise in Human Trialsmsn.com - March 18 at 2:35 AMTARS Apr 2024 25.000 callfinance.yahoo.com - March 16 at 2:01 PMTARS Apr 2024 17.500 putfinance.yahoo.com - March 16 at 1:17 AMTARS Apr 2024 12.500 callfinance.yahoo.com - March 16 at 1:17 AMThis Chewable Tablet Can Protect Humans From Lyme Disease Brought by Tickstechtimes.com - March 15 at 3:15 PMA Pill That Kills Ticks Is a Promising New Weapon Against Lyme Diseasewired.com - March 15 at 3:15 PMTarsus Pharmaceuticals (NASDAQ:TARS) Shares Up 6.9%marketbeat.com - March 15 at 12:37 PMAnalysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)markets.businessinsider.com - March 13 at 7:29 PMTarsus launches a 'Mite Party' for new Xdemvy marketing campaignfiercepharma.com - March 12 at 4:05 PMTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.7%marketbeat.com - March 11 at 12:44 PMTarsus Pharmaceuticals throws a Mite Party to combat demodex blepharitismmm-online.com - March 7 at 7:42 PMTarsus Pharmaceuticals (NASDAQ:TARS) Price Target Increased to $44.00 by Analysts at Jefferies Financial Groupmarketbeat.com - March 7 at 8:20 AMRTW Investments LP Grows Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)marketbeat.com - March 6 at 11:00 AMHow Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%zacks.com - March 6 at 10:56 AMTarsus to Participate at Upcoming Investor Conferencesglobenewswire.com - March 5 at 4:30 PMTarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitisglobenewswire.com - March 5 at 8:30 AMConnor Clark & Lunn Investment Management Ltd. Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)marketbeat.com - March 4 at 6:02 AMTarsus Pharmaceuticals (NASDAQ:TARS) Sees Unusually-High Trading Volume Following Analyst Upgrademarketbeat.com - March 3 at 1:03 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesIs UnitedHealth Group Stock a Strong Buy or a Falling Knife?March 5, 2024 7:08 AMView Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?Kohl’s Corporation: This Offprice Retailer Is Ready To RallyMarch 1, 2024 10:55 AMView Kohl’s Corporation: This Offprice Retailer Is Ready To RallyAdobe Stock Reaches Turning Point as Market Outlook ResetsMarch 15, 2024 8:55 AMView Adobe Stock Reaches Turning Point as Market Outlook ResetsIntuitive Machines: Charting a Course Among the StarsMarch 21, 2024 11:30 AMView Intuitive Machines: Charting a Course Among the StarsThese Are The Most Upgraded Stocks From Q1March 25, 2024 10:10 AMView These Are The Most Upgraded Stocks From Q1All Headlines Company DescriptionsKodiak SciencesNASDAQ:KODKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Sutro BiopharmaNASDAQ:STROSutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Tarsus PharmaceuticalsNASDAQ:TARSTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.